These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

816 related items for PubMed ID: 11839685

  • 1. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
    Maulik G, Kijima T, Ma PC, Ghosh SK, Lin J, Shapiro GI, Schaefer E, Tibaldi E, Johnson BE, Salgia R.
    Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685
    [Abstract] [Full Text] [Related]

  • 2. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
    Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, Johnson BE, Salgia R.
    Cancer Res; 2003 Oct 01; 63(19):6272-81. PubMed ID: 14559814
    [Abstract] [Full Text] [Related]

  • 3. Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer.
    Maulik G, Madhiwala P, Brooks S, Ma PC, Kijima T, Tibaldi EV, Schaefer E, Parmar K, Salgia R.
    J Cell Mol Med; 2002 Oct 01; 6(4):539-53. PubMed ID: 12611639
    [Abstract] [Full Text] [Related]

  • 4. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells.
    Hov H, Holt RU, Rø TB, Fagerli UM, Hjorth-Hansen H, Baykov V, Christensen JG, Waage A, Sundan A, Børset M.
    Clin Cancer Res; 2004 Oct 01; 10(19):6686-94. PubMed ID: 15475459
    [Abstract] [Full Text] [Related]

  • 5. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
    Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, Stiles CD, Griffin JD, Johnson BE, Salgia R.
    Oncogene; 2000 Jul 20; 19(31):3521-8. PubMed ID: 10918610
    [Abstract] [Full Text] [Related]

  • 6. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.
    Li Y, Lal B, Kwon S, Fan X, Saldanha U, Reznik TE, Kuchner EB, Eberhart C, Laterra J, Abounader R.
    Cancer Res; 2005 Oct 15; 65(20):9355-62. PubMed ID: 16230398
    [Abstract] [Full Text] [Related]

  • 7. Adaptor molecule Crk is required for sustained phosphorylation of Grb2-associated binder 1 and hepatocyte growth factor-induced cell motility of human synovial sarcoma cell lines.
    Watanabe T, Tsuda M, Makino Y, Ichihara S, Sawa H, Minami A, Mochizuki N, Nagashima K, Tanaka S.
    Mol Cancer Res; 2006 Jul 15; 4(7):499-510. PubMed ID: 16849525
    [Abstract] [Full Text] [Related]

  • 8. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.
    Webb CP, Hose CD, Koochekpour S, Jeffers M, Oskarsson M, Sausville E, Monks A, Vande Woude GF.
    Cancer Res; 2000 Jan 15; 60(2):342-9. PubMed ID: 10667586
    [Abstract] [Full Text] [Related]

  • 9. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells.
    Song L, Turkson J, Karras JG, Jove R, Haura EB.
    Oncogene; 2003 Jul 03; 22(27):4150-65. PubMed ID: 12833138
    [Abstract] [Full Text] [Related]

  • 10. Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells.
    Comoglio PM.
    EXS; 1993 Jul 03; 65():131-65. PubMed ID: 8380735
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F, Engst S, Yamaguchi K, Yu P, Won KA, Mock L, Lou T, Tan J, Li C, Tam D, Lougheed J, Yakes FM, Bentzien F, Xu W, Zaks T, Wooster R, Greshock J, Joly AH.
    Cancer Res; 2009 Oct 15; 69(20):8009-16. PubMed ID: 19808973
    [Abstract] [Full Text] [Related]

  • 12. Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells.
    Ye M, Hu D, Tu L, Zhou X, Lu F, Wen B, Wu W, Lin Y, Zhou Z, Qu J.
    Invest Ophthalmol Vis Sci; 2008 Feb 15; 49(2):497-504. PubMed ID: 18234991
    [Abstract] [Full Text] [Related]

  • 13. Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells.
    Yamamoto N, Mammadova G, Song RX, Fukami Y, Sato K.
    J Cell Sci; 2006 Nov 15; 119(Pt 22):4623-33. PubMed ID: 17062641
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of the met receptor in mesothelioma.
    Mukohara T, Civiello G, Davis IJ, Taffaro ML, Christensen J, Fisher DE, Johnson BE, Jänne PA.
    Clin Cancer Res; 2005 Nov 15; 11(22):8122-30. PubMed ID: 16299245
    [Abstract] [Full Text] [Related]

  • 15. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
    Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T, Chen Q, Ho SY, Li L, Kaufman S, McDorman K, Cattley RC, Sun J, Elliott G, Zhang K, Feng X, Jia XC, Green L, Radinsky R, Kendall R.
    Cancer Res; 2006 Feb 01; 66(3):1721-9. PubMed ID: 16452232
    [Abstract] [Full Text] [Related]

  • 16. Autocrine and/or paracrine growth of aggressive ATLL cells caused by HGF and c-Met.
    Onimaru Y, Tsukasaki K, Murata K, Imaizumi Y, Choi YL, Hasegawa H, Sugahara K, Yamada Y, Hayashi T, Nakashima M, Taguchi T, Mano H, Kamihira S, Tomonaga M.
    Int J Oncol; 2008 Oct 01; 33(4):697-703. PubMed ID: 18813782
    [Abstract] [Full Text] [Related]

  • 17. Increase in hepatocyte growth factor receptor tyrosine kinase activity in renal carcinoma cells is associated with increased motility partly through phosphoinositide 3-kinase activation.
    Nakamura T, Kanda S, Yamamoto K, Kohno T, Maeda K, Matsuyama T, Kanetake H.
    Oncogene; 2001 Nov 15; 20(52):7610-23. PubMed ID: 11753639
    [Abstract] [Full Text] [Related]

  • 18. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion.
    Ma PC, Tretiakova MS, Nallasura V, Jagadeeswaran R, Husain AN, Salgia R.
    Br J Cancer; 2007 Aug 06; 97(3):368-77. PubMed ID: 17667909
    [Abstract] [Full Text] [Related]

  • 19. A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway.
    Tiran Z, Oren A, Hermesh C, Rotman G, Levine Z, Amitai H, Handelsman T, Beiman M, Chen A, Landesman-Milo D, Dassa L, Peres Y, Koifman C, Glezer S, Vidal-Finkelstein R, Bahat K, Pergam T, Israel C, Horev J, Tsarfaty I, Ayalon-Soffer M.
    Clin Cancer Res; 2008 Jul 15; 14(14):4612-21. PubMed ID: 18628476
    [Abstract] [Full Text] [Related]

  • 20. beta-Catenin and actin reorganization in HGF/SF response of ST14A cells.
    Soldati C, Biagioni S, Poiana G, Augusti-Tocco G.
    J Neurosci Res; 2008 Apr 15; 86(5):1044-52. PubMed ID: 17975841
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.